Home
>
US Stocks
>
Mirati Therapeutics Inc
Mirati Therapeutics Inc
MRTX

Mirati Therapeutics Inc

$174.347.09%

1D

1W

1M

1Y

3Y

5Y

Key Stats

Open
178.51
Today Low/High
171.93 / 178.51
52 Week Low/High
$130.6 / $249.42
P/E ratio
-14.5714
Market Cap
$7.15B

Company Details

Mirati Therapeutics is a late-stage biotechnology company whose mission is to discover, design and deliver breakthrough therapies to transform the lives of patients with cancer and their loved ones. The company is relentlessly focused on bringing forward therapies that address areas of high unmet need, including lung cancer, and advancing a pipeline of novel therapeutics targeting the genetic and immunological drivers of cancer. Mirati is using its scientific expertise to develop novel solutions in two registration-enabling programs: adagrasib (MRTX849), an investigational small molecule, potent and selective KRAS G12C inhibitor, as monotherapy and in combination with other agents, and sitravatinib, an investigational spectrum-selective inhibitor of receptor tyrosine kinases in combination with checkpoint inhibitor therapies. Mirati is also advancing its differentiated preclinical portfolio, including MRTX1133, an investigational KRAS G12D inhibitor, and other oncology discovery programs. Unified for patients, Mirati's vision is to unlock the science behind the promise of a life beyond cancer.
Organisation
Mirati Therapeutics Inc
Headquaters
San Diego, California, US
Employees
200
Industry
Health Technology
CEO
Charles Baum

Discover more

Frequently Asked Questions

What is Mirati Therapeutics Inc share price today

Can Indians buy Mirati Therapeutics Inc shares?

How can I buy Mirati Therapeutics Inc shares from India?

Can Fractional shares of Mirati Therapeutics Inc be purchased?

What are the documents required to start investing in Mirati Therapeutics Inc stocks?

We are a SEBI registered investement advisor